The patient experienced immediate relief from the symptoms, and the blood cultures and the pericardial fluid were negative. A tuberculin dermal test was negative, and a direct examination of the sputum and pericardial fluid revealed the absence of acidresistant bacteria. A histological examination of the pericardial fluid revealed the presence of malignant cells. Computed tomography (CT) of the thorax showed a mass in the anterior mediastinum located anterior to the heart beginning at 2 cm below the level of the sternal notch and reaching the origin of the pulmonary artery (Figures 2). Also, the right lung parenchyme adjacent to the mass, the great vessels, and the pericardium was invaded by the tumor. Pericardial and bilateral pleural effusion was evident on CT. A biopsy taken via mediastinotomy was consistent with Hodgkin’s disease of the nodular sclerosing type.
Figure 2: Computed tomography of the patient showing the mediastinal mass (arrow).
Furthermore, early recognition with successful treatment of MPE can prolong and improve the quality of life, especially in patients with a disease that is potentially responsive to current therapies. A wide variety of approaches have been reported to be effective for MPE, including the following: repeat pericardiocentesis, surgical drainage of the pericardium with a pericardial window, indwelling catheter drainage with the pericardial instillation of chemotherapeutic agents such as tetracycline, thiotepa, or bleomycin, a partial or total pericardectomy, a pericardioperitoneal shunt, a thoracoscopy, radiotherapy, and percutaneous balloon pericardiostomy.[5]
Hodgkin’s lymphoma in newly diagnosed patients most commonly presents with mediastinal disease and is unique as a lymphoma in that the neoplastic cell component is associated with an inflammatory host response that may obscure the neoplastic cell populace. Hodgkin’s lymphoma is divided into two types: (i) classic Hodgkin’s lymphoma which encompasses the spectrum of nodular sclerosing, mixed cellularity, and lymphocyte-depleted forms and (ii) diffuse nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL).[6] Hodgkin’s lymphoma is also a rare malignancy, with an incidence rate of about 2-4 per 100.000 per year.[7] Figure 1: An echocardiogram of the patient showing the pericardial effusion (arrow) that caused cardiac tamponade.
The prevalence in women peaks in the third decade
and then falls, but in men it remains fairly constant
after the third decade of life. Diagnosis of Hodgkin’s
lymphoma is based on the finding of Hodgkin/Reed-
Sternberg cells in an appropriate cellular background
of reactive leucocytes and, in some cases, fibrosis.
In the developed world, nodular sclerosing classical
Hodgkin’s lymphoma accounts for over two-thirds of all
cases. Lymphocyte-rich classical Hodgkin’s lymphoma
is a newly defined entity and is closely related to the
disorder previously classified as diffuse lymphocytepredominant
Hodgkin’s disease.
The presenting features of this disease are many.[7]
Most patients have asymptomatic lump, typically in the
lower neck or supraclavicular region. Mediastinal masses
are frequent and are sometimes discovered after routine
chest radiography. Patients may complain of chest
discomfort with a cough or dyspnea. About 25% of
patients have systemic symptoms at presentation, for
example fatigue, fever, weight loss, and night sweats.
Pruritus and intermittent fevers usually associated
with night sweats are classic symptoms of Hodgkin’s
lymphoma.[7]
Retter and et al.[8] reported on a case with MPE
and Hodgkin’s lymphoma who was receiving her
second round of chemotherapy for relapsing lymphoma.
However, our patient’s presenting symptom was only
MPE. Gabrys et al.[9] reported seven patients with
hematologic disorders and MPE, with only one patient
having MPE along with Hodgkin’s lymphoma. Although
pleural effusions are common in patients with lymphoma,
pericardial effusions are rare. We could find only three
previous reports of a patient with Hodgkin’s or non-
Hodgkin’s lymphoma suffering a massive pericardial
effusion.[8-10]
Due to the rarity of pericardial effusions and
Hodgkin’s lymphoma, we present our findings with
the hope that more research could be conducted on this
topic.
Declaration of conflicting interests
Funding<
The authors declared no conflicts of interest with respect
to the authorship and/or publication of this article.
The authors received no financial support for the
research and/or authorship of this article.
1) Bisel HF, Wroblewski F, Ladue JS. Incidence and clinical
manifestations of cardiac metastases. J Am Med Assoc
1953;153:712-5.
2) Celermajer DS, Boyer MJ, Bailey BP, Tattersall MH.
Pericardiocentesis for symptomatic malignant pericardial
effusion: a study of 36 patients. Med J Aust 1991;154:19-22.
3) Little AG, Kremser PC, Wade JL, Levett JM, DeMeester
TR, Skinner DB. Operation for diagnosis and treatment of
pericardial effusions. Surgery 1984;96:738-44.
4) Park JS, Rentschler R, Wilbur D. Surgical management
of pericardial effusion in patients with malignancies.
Comparison of subxiphoid window versus pericardiectomy.
Cancer 1991;67:76-80.
5) Vaitkus PT, Herrmann HC, LeWinter MM. Treatment of
malignant pericardial effusion. JAMA 1994;272:59-64.
6) Yousem SA, Weiss LM, Colby TV. Primary pulmonary
Hodgkin’s disease. A clinicopathologic study of 15 cases.
Cancer 1986;57:1217-24.
7) Cartwright R, Brincker H, Carli PM, Clayden D, Coebergh
JW, Jack A, et al. The rise in incidence of lymphomas in
Europe 1985-1992. Eur J Cancer 1999;35:627-33.
8) Retter A, Ardeshna KM, O’Driscoll A. Cardiac tamponade
in Hodgkin lymphoma. Br J Haematol 2007;138:2.